🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕 Our study, led by the amazing David Jiménez 🇪🇸, is now published in Eur Heart J 🚨 European Society of Cardiology Journals 🫁🫀In stable patients with acute #PE, the eStiMaTe©️ multimarker calculator substantially improved mortality risk stratification beyond the ESC model 🔢🆚🚦 🔗 academic.oup.com/eurheartj/adva…

Hello #CardioTwitter 👋👋! If you're attending #EuroPCR, we'd love to meet you at our desk and give you a brief History lesson 😉 and your invitation for our #20yearsOfEuroIntervention cocktail 🎉 on Thursday evening.

JUST OUT @ the 20th anniversary PCRonline 🫀 #EuroPCR25 edition of EuroIntervention ! Our expert review on the latest in leaflet modification in #TAVR by my partner Sunny Goel et al eurointervention.pcronline.com/article/leafle… Jaffar Khan DoctorKini George Dangas, MD, MACC, MSCAI Sahil Khera Parasuram Krishnamoorthy MD

#EuroPCR simultaneous publication. In the 4D-ACS trial, one-month DAPT followed by prasugrel 5 mg monotherapy in ACS patients treated with a drug-coated stent reduced NACE by 49%, primarily driven by a 77% reduction in bleeding events, compared to 12-month DAPT. What I find

#EuroPCR2025 A prospective study evaluating next-day and 48-hour discharge after alternative access #TAVI (subclavian/axillary, carotid, transapical) found no increase in 30-day readmission or mortality across discharge strategies. Rodrigo Bagur 🇦🇷🇨🇦 #EAPCI

🎥In this interview, Valeria Paradies and Chiara De Biase discuss the new expert consensus document on sex-specific risks, tailored antithrombotic strategies, and improving female representation in ACS trials published in EuroIntervention with the #EAPCI and the European Society of Cardiology working group

🎈DCB vs. DES for ostial left circumflex lesions — what does the data say? Here are the key takeaways from this eye-opening study presented in the “Innovative strategies for coronary interventions” session at #EuroPCR 2025, explained by Francesco Tartaglia with insights from

I could not have imagined a better way to mark this 20th anniversary than by sharing it with the many individuals who read and contribute to EuroIntervention. This milestone is not only ours—as editors, editorial team, and publishers—but belongs to the entire interventional

Our sincere congratulations to Lars Wallentin and Stefan James who received the Andreas Grüntzig Ethica Award 🏆 during #EuroPCR 2025, on behalf of a wider team of cardiovascular registry experts who have contributed in an extraordinary way to the PCR mission. "The purpose of

🎬 That’s a wrap for the 2025 edition of #EuroPCR From tough procedures to tricky cases and the real-world challenges behind them, the past four days were all about finding solutions together 💪 👀 Check out the Closing Ceremony and relive the best bits 👋 See you next year

What a night!

Need to do better for #PE risk stratification, beyond reductionist models. In an European Society of Cardiology Journals #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great work by David Jiménez 🇪🇸 manuel monreal et al #RIETE! Honored to be a part of it 👇: tinyurl.com/trpmzbrd

In patients with CCS undergoing PCI, ticagrelor monotherapy after 3 months of DAPT showed similar 1-year ischaemic and bleeding outcomes compared to ticagrelor-based #DAPT, regardless of high ischaemic risk status. Mauro Gitto ow.ly/6Afj50VYwKa #EAPCI #TWILIGHTTrial

In this prespecified subanalysis of the OCTIVUS trial, OCT- and IVUS-guided PCI showed similar 2-year target vessel failure rates in patients with and without ACS. Increased contrast use with OCT did not lead to higher rates of contrast-induced nephropathy.

I’m always eager for updates on antiplatelet agents, so I thought it was worth sharing that CeleBrate, the pivotal Phase 3 trial of the subcutaneous GPIIb/IIIa inhibitor zalunfiban, has been completed. Results are expected in Q3 2025—possibly at AHA? The drug is being developed

In the field of interventional cardiology, today’s news is that Boston Scientific Corporation has announced the discontinuation of global sales of its ACURATE neo2™ and ACURATE Prime™ aortic valve systems. Over the years, various iterations of this valve have been evaluated in

🚀 Great news! REC: Interventional Cardiology is now indexed in PubMed. 🎯 Articles from Volume 6 (2024) will be progressively added to the platform in the coming weeks. This is a recognition of scientific rigor, the collective work of authors, reviewers, committees, staff

Upon the occasion of #EuroPCR, the PCRonline Editorial Board, led by Editor-in-Chief Salvatore Brugaletta and the Journal Club team, led by Journal Club Chair Nicola Ryan, could meet up in person, exchange ideas and discuss content strategy. We are so grateful 🙏 to each and every

This comprehensive review by Goel et al. explores the principles, procedural details, and outcomes of techniques including BASILICA, ShortCut, UNICORN, and newer methods like CATHEDRAL and Splitter. Each approach is discussed in the context of anatomical challenges, device

Coronary obstruction is a rare but serious complication during transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, which is associated with high mortality. This review explores various leaflet modification techniques designed to mitigate